pd 98059 has been researched along with Leukemia in 11 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, in this study, we show for the first time that PD could protect the leukemia cells independent of ERK pathway inhibition, besides, we also report a detailed mechanism for antiapoptotic effect of LY in HL-60 cells against the cytotoxicity induced by a boswellic acid analog BA145." | 3.79 | Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. ( Andotra, SS; Bhat, WW; Bhushan, S; Guru, SK; Joshi, A; Kumar, A; Kumar, S; Malik, FA; Pathania, AS; Saxena, AK; Shah, BA; Sharma, PR; Singh, J; Taneja, SC, 2013) |
| "Four cell lines and all chronic lymphocytic leukemia cells were killed in 6 hours by vinblastine alone." | 1.36 | Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. ( Albershardt, TC; Bates, DJ; Eastman, A; Lowrey, CH; Salerni, BL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pathania, AS | 1 |
| Joshi, A | 1 |
| Kumar, S | 1 |
| Guru, SK | 1 |
| Bhushan, S | 1 |
| Sharma, PR | 1 |
| Bhat, WW | 1 |
| Saxena, AK | 1 |
| Singh, J | 1 |
| Shah, BA | 1 |
| Andotra, SS | 1 |
| Taneja, SC | 1 |
| Malik, FA | 1 |
| Kumar, A | 1 |
| Song, H | 1 |
| Kim, KE | 1 |
| Hur, D | 1 |
| Lim, JS | 1 |
| Yang, Y | 1 |
| Cho, BJ | 1 |
| Kim, CH | 1 |
| Kim, T | 1 |
| Bang, S | 1 |
| Lee, WJ | 1 |
| Park, H | 1 |
| Cho, D | 1 |
| Salerni, BL | 1 |
| Bates, DJ | 1 |
| Albershardt, TC | 1 |
| Lowrey, CH | 1 |
| Eastman, A | 1 |
| Gao, N | 1 |
| Budhraja, A | 1 |
| Cheng, S | 1 |
| Liu, EH | 1 |
| Huang, C | 1 |
| Chen, J | 1 |
| Yang, Z | 1 |
| Chen, D | 1 |
| Zhang, Z | 1 |
| Shi, X | 1 |
| Mas, VM | 1 |
| Hernandez, H | 1 |
| Plo, I | 1 |
| Bezombes, C | 1 |
| Maestre, N | 1 |
| Quillet-Mary, A | 1 |
| Filomenko, R | 1 |
| Demur, C | 1 |
| Jaffrézou, JP | 1 |
| Laurent, G | 1 |
| Minami, Y | 1 |
| Yamamoto, K | 1 |
| Kiyoi, H | 1 |
| Ueda, R | 1 |
| Saito, H | 1 |
| Naoe, T | 1 |
| Li, DJ | 1 |
| Zhang, YZ | 1 |
| Huang, W | 1 |
| Meng, FK | 1 |
| Hazlehurst, LA | 1 |
| Argilagos, RF | 1 |
| Dalton, WS | 1 |
| Gocek, E | 1 |
| Kiełbiński, M | 1 |
| Marcinkowska, E | 1 |
| Champelovier, P | 1 |
| El Atifi, M | 1 |
| Pautre, V | 1 |
| Rostaing, B | 1 |
| Berger, F | 1 |
| Seigneurin, D | 1 |
| Dai, Y | 1 |
| Yu, C | 1 |
| Singh, V | 1 |
| Tang, L | 1 |
| Wang, Z | 1 |
| McInistry, R | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vinblastine Versus Oral Hydroxiurea in Newly Diagnosed AML With Hyperleukocytosis: a Phase 2 Clinical Study[NCT05062278] | Phase 2 | 46 participants (Anticipated) | Interventional | 2021-07-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for pd 98059 and Leukemia
| Article | Year |
|---|---|
Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059.
Topics: Apoptosis; Chromones; Flavonoids; HL-60 Cells; Humans; Leukemia; MAP Kinase Signaling System; Morpho | 2013 |
IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells.
Topics: Anthracenes; Cell Line, Tumor; Cytotoxicity, Immunologic; Flavonoids; Gene Expression Regulation, Ne | 2008 |
Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cycloheximide; Cytoprotection; Drug Screening Assays, Antit | 2010 |
Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Caspases; Cytochromes c; Extracellular Sign | 2011 |
Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetylcysteine; Androstadienes; Antibiotics, Antineoplastic; | 2003 |
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.
Topics: Apoptosis; bcl-X Protein; Cell Division; Cell Line; Chromones; Dose-Response Relationship, Drug; Dow | 2003 |
[To inhibit ERK for enhancing chemotherapy sensitivity of drug-resistance cell lines of leukemia and ovarian carcinoma].
Topics: Apoptosis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flavonoids; HL-60 Cells; Humans; Le | 2003 |
Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; | 2007 |
Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation.
Topics: Active Transport, Cell Nucleus; Calcitriol; Cell Nucleus; Cells, Cultured; Chromones; Enzyme Inhibit | 2007 |
Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Topics: Anthracenes; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Division; Cell L | 2008 |
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Butadienes; Caspas | 2001 |